A.P. Møller – Mærsk is a global leader in the shipping and logistics industry, with a long history of innovation and success. Recently, several prominent financial institutions have updated their price targets for the company, reflecting their outlook on its future performance.
Bernstein has raised its price target for A.P. Møller – Mærsk to 9,350 Danish krone, while maintaining an underperform rating. This suggests that they believe the stock may be overvalued and could underperform relative to the market.
On the other hand, Carnegie has increased its price target to 12,500 Danish krone, with a hold rating. This indicates a more positive outlook on the company’s prospects, but suggests that there may be limited upside potential at current levels.
JP Morgan has raised its price target to 7,900 Danish krone, with an underweight rating. This implies that they believe the stock is overvalued and may underperform compared to its peers.
In contrast, HSBC has lowered its price target to 14,000 Danish krone, while maintaining a buy rating. This indicates that they see potential for the stock to outperform the market, despite the reduced target price.
Moving on to other companies in the market, Apotea has seen its price target raised by Carnegie to 85 krone, with a hold rating. Meanwhile, SEB has initiated coverage on the company with a buy recommendation and a price target of 104 krone.
Boliden has had its price target raised by Citigroup to 325 krone, with a neutral rating. Clas Ohlson’s price target has been increased by Carnegie to 290 krone, with a buy rating.
Demant has had its price target lowered by JP Morgan to 274 Danish krone, with an overweight rating. Embellence has seen its price target raised by Handelsbanken to 40 krone, with a buy rating.
Fractal Gaming’s price target has been raised by both Carnegie and SEB, to 43 krone, with hold ratings. Genmab’s price target has been increased by Carnegie to 2,288 Danish krone, with a buy rating. Goldman Sachs has raised its price target to 1,785 Danish krone, with a neutral rating, while Cowen has lowered its target to 1,360 Danish krone, with a hold rating.
Hufvudstaden has had its price target lowered by Pareto Securities to 125 krone, with a hold rating. Holmen’s price target has been raised by Carnegie to 435 krone, with a hold rating, while SEB has raised its target to 451 krone, with a buy rating.
Jyske Bank’s price target has been increased by Barclays to 561 Danish krone, with an overweight rating. Mentice has had its price target lowered by Pareto Securities to 18 krone, with a hold rating.
Norwegian’s price target has been raised by Pareto Securities to 16 Norwegian krone, with a buy rating. Rugvista’s price target has been increased by Carnegie to 70 krone, with a buy rating. Rusta’s price target has been raised by SEB to 100 krone, with a buy rating.
Securitas has had its price target lowered by SEB to 175 krone, with a buy rating. Sinch’s price target has been raised by SEB to 31 krone, with a buy rating. Sagax’s price target has been lowered by SEB to 232 krone, with a hold rating.
Shamaran’s price target has been raised by Carnegie to 0.23 Canadian dollars, with a buy rating. Schibsted Marketplaces’ price target has been increased by Carnegie to 400 Norwegian krone, with a buy rating.
Storebrand’s price target has been raised by JP Morgan to 117 Norwegian krone, with an underweight rating. Sobi’s price target has been lowered by Barclays to 350 krone, with an overweight rating.
Zealand Pharma’s price target has been lowered by Goldman Sachs to 806 Danish krone, with a buy rating, and by SEB to 780 Danish krone, also with a buy rating. Zymes Technologies’ price target has been lowered by Pareto Securities to 16 Norwegian krone, with a hold rating.
Overall, these updated price targets reflect the varying outlooks of different financial institutions on the future performance of these companies. Investors should carefully consider this information in their decision-making process.